UK In-Vitro Diagnostic Market

UK In-Vitro Diagnostics Market Overview

The UK In-Vitro Diagnostics Market size was valued at USD 2.35 billion in 2023, and is predicted to reach USD 2.79 billion by 2030, at a CAGR of 2.1% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. These tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.

These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, in-vitro experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Rapid Healthcare Expenditure Growth Drives In-Vitro Diagnostics Market

The rapid increase in healthcare expenditure is significantly driving the growth of the in-vitro diagnostics market. According to OECD report, UK allocates USD 5493 per capita on health, that is equal to 11.3% of the nation’s GDP. This increased investment in healthcare services directly boosts the demand for greater accessibility and affordability of diagnostic solutions, including in-vitro diagnostics tests, for the population. As healthcare systems modernize and expand to meet growing demands, there is a heightened need for accurate and timely diagnostic tools to support disease prevention, early detection, and personalized treatment strategies. 

Rising Chronic Disease Rates Fuel Demand for In-Vitro Diagnostics in the UK

The prevalence of chronic disease such as cancer in the UK has been steadily increasing over the years, thereby propelling the demand for in-vitro diagnostics. According to McMillan Cancer Support, in UK, the number of people living with cancer was 3 million in the year 2020 which is projected to increase to 4 million by 2030 and further to 5.3 million by 2040, annually, UK witnesses around 167,000 cancer-related deaths, equivalent to an average of 460 fatalities per day. As cancer remains a significant contributor to mortality in the UK, there's an escalating demand for reliable diagnostic tools such as in-vitro diagnostics facilitating early detection, precise diagnosis, and personalized treatment strategies.

High Research, Development, and Regulatory Approval Costs Hinder Vitro Diagnostics Market Growth

High costs associated with research, development, and regulatory approval are significant factors restraining the in-vitro diagnostics market growth. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development.

This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability. Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing Solutions in IVD Creates Opportunity

Point-of-care testing (POCT) is poised to be a significant driver of growth in the in-vitro diagnostics (IVD) market in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions. By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

Competitive Landscape

The promising players operating in the UK in-vitro diagnostics industry include Roche Holding AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., and Bio-Rad Laboratories, Inc., and others.

UK In-Vitro Diagnostic Market Key Segments

By Product & Service                

• Reagents & Consumables            

  • Clinical Chemistry Reagents        

  • Immunoassay Reagents (ELISA/CLIA)        

  • Molecular Master Mixes        

  • Hematology Controls        

• Instruments & Devices            

  • Chemistry Analyzers        

  • Immunoassay Systems        

  • Molecular Thermocyclers/Sequencers        

  • Hematology Analyzers        

  • POC Devices        

• Software & Services            

  • LIS, Data Analytics        

  • CRO/Testing Services        

By Technique                

• Clinical Chemistry            

  • Metabolites        

  • Electrolytes        

  • Enzymes        

• Immunoassays            

  • ELISA / CLIA / CMIA        

  • Lateral-flow Rapid Tests        

  • Immunofluorescence        

• Molecular Diagnostics            

  • PCR        

  • Isothermal NAAT        

  • NGS        

  • In-situ Hybridization        

• Hematology & Coagulation            

  • CBC Analyzers        

  • Coagulation Panels        

• Microbiology            

  • Culture & Sensitivity        

  • MALDI-TOF        

  • Molecular ID        

• Urinalysis & Body Fluids            

• Other Techniques            

By Testing Site / Channel                

• Central & Reference Laboratories            

• Hospital & Physician Labs            

• Point-of-Care & Retail            

• Home & Self-Testing            

By Application            

• Infectious Diseases            

• Oncology            

• Cardiovascular Health            

• Endocrinology & Diabetes            

• Nephrology            

• Genetic & Prenatal Testing            

• Autoimmune Disorders            

• Drug Monitoring & Toxicology            

• Blood Screening & Typing            

• Other Indications            

Key Players

• Roche Holding AG

• Abbott Laboratories

• Thermo Fisher Scientific Inc

• Danaher Corporation

• Becton, Dickinson and Company

• Siemens Healthineers AG

• bioMérieux SA

• Sysmex Corporation

• QIAGEN N.V.

• Bio-Rad Laboratories, Inc.

Report Scope and Segmentation